Four things to know about the company’s second-quarter financial performance:
- Medtronic saw a 3 percent dip in reported revenue, but saw a 2 percent increase in organic growth.
- Medtronic brought in $2.19 billion from its neuroscience portfolio
- The company reported a GAAP diluted earnings per share of $0.32, a decrease of 67 percent, and a non-GAAP diluted earnings per share of $1.30, a decrease of 2 percent.
- The company said in a Nov. 22 news release that it expects to see more organic revenue growth during the second half of the fiscal year.
